MALAT1 and acute myeloid leukemia: As follows, in the clinical setting AML patients carrying the ETV6-NTRK3 gene fusion and associated MALAT1 overexpression can exhibit a better therapeutic response to NTRK3 inhibitor, AZ-23 (114).